Search research articles
Contact Us
Filters
Showing results (291-300 of 358) with videos related to
Page
of 36
Sort By:
Plos Pathogens
|
May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
NPJ Vaccines
|
May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Boris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Viruses
|
July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment
Raabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
The Journal of Infectious Diseases
|
March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial
Supachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Ebiomedicine
|
September 11, 2022
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8<sup>+</sup> T cells
Hiroshi Takata, Juyeon C Kakazu, Julie L Mitchell, et al.
The Lancet. Infectious Diseases
|
August 17, 2024
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial
Kayvon Modjarrad, Paul T Scott, Melanie McCauley, et al.
Journal of Virus Eradication
|
November 30, 2020
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
Eugène D M B Kroon, Jintanat Ananworanich, Amélie Pagliuzza, et al.
The Journal of Infectious Diseases
|
October 3, 2017
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
Julie A Ake, Alexandra Schuetz, Poonam Pegu, et al.
Journal of Virology
|
November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
David Easterhoff, Justin Pollara, Kan Luo, et al.
Cell
|
November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys
Dan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
Page
of 36
Search research articles
Search
Showing results (291-300 of 358) with videos related to
Sort By:
Page
of 36
Plos Pathogens
|
May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
NPJ Vaccines
|
May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Boris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Viruses
|
July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment
Raabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
The Journal of Infectious Diseases
|
March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial
Supachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Ebiomedicine
|
September 11, 2022
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8<sup>+</sup> T cells
Hiroshi Takata, Juyeon C Kakazu, Julie L Mitchell, et al.
The Lancet. Infectious Diseases
|
August 17, 2024
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial
Kayvon Modjarrad, Paul T Scott, Melanie McCauley, et al.
Journal of Virus Eradication
|
November 30, 2020
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
Eugène D M B Kroon, Jintanat Ananworanich, Amélie Pagliuzza, et al.
The Journal of Infectious Diseases
|
October 3, 2017
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
Julie A Ake, Alexandra Schuetz, Poonam Pegu, et al.
Journal of Virology
|
November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
David Easterhoff, Justin Pollara, Kan Luo, et al.
Cell
|
November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys
Dan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
Page
of 36